跳到正文
原文
STAT· @statnews · X·· 2026-10-16精选AI 评分62
AI 导读

欧洲监管机构已推荐批准RevMed的Rasonque用于胰腺癌。EMA表示此次审评用时不到150天,而标准审评通常持续一年。

推荐理由

EMA对RevMed胰腺癌药物给出批准推荐,审评用时不到150天,可与标准审评周期对照理解其节奏。

正文

European regulators have now recommended the approval of RevMed's Rasonque for pancreatic cancer.

The European Medicines Agency said the review took less than 150 days, compared to a standard review, which often lasts a year. https://trib.al/PfSmaqM

来源:STAT · x.com